药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Zuclopenthixol
Lumretuzumab
The risk or severity of adverse effects can be increased when Lumretuzumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Tovetumab
The risk or severity of adverse effects can be increased when Tovetumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Dacetuzumab
The risk or severity of adverse effects can be increased when Dacetuzumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Bimagrumab
The risk or severity of adverse effects can be increased when Bimagrumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Blosozumab
The risk or severity of adverse effects can be increased when Blosozumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Mavrilimumab
The risk or severity of adverse effects can be increased when Mavrilimumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Inebilizumab
The risk or severity of adverse effects can be increased when Inebilizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Plozalizumab
The risk or severity of adverse effects can be increased when Plozalizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Mogamulizumab
The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Mirvetuximab Soravtansine
The risk or severity of adverse effects can be increased when Mirvetuximab Soravtansine is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Bococizumab
The risk or severity of adverse effects can be increased when Bococizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Indusatumab vedotin
The risk or severity of adverse effects can be increased when Indusatumab vedotin is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Fresolimumab
The risk or severity of adverse effects can be increased when Fresolimumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Dusigitumab
The risk or severity of adverse effects can be increased when Dusigitumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Fezakinumab
The risk or severity of adverse effects can be increased when Fezakinumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Ensituximab
The risk or severity of adverse effects can be increased when Ensituximab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Tanezumab
The risk or severity of adverse effects can be increased when Tanezumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Labetuzumab govitecan
The risk or severity of adverse effects can be increased when Labetuzumab govitecan is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Vanucizumab
The risk or severity of adverse effects can be increased when Vanucizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
GS-5745
The risk or severity of adverse effects can be increased when GS-5745 is combined with Trastuzumab deruxtecan.